RU2020111934A - Способы лечения фиброзного рака - Google Patents

Способы лечения фиброзного рака Download PDF

Info

Publication number
RU2020111934A
RU2020111934A RU2020111934A RU2020111934A RU2020111934A RU 2020111934 A RU2020111934 A RU 2020111934A RU 2020111934 A RU2020111934 A RU 2020111934A RU 2020111934 A RU2020111934 A RU 2020111934A RU 2020111934 A RU2020111934 A RU 2020111934A
Authority
RU
Russia
Prior art keywords
sap
lirinolide
agonist
paragraphs
administration
Prior art date
Application number
RU2020111934A
Other languages
English (en)
Russian (ru)
Inventor
Сьюзан БРУН
Элизабет ТРЕХУ
Марк ЛЮФЕР
Original Assignee
Промедиор, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Промедиор, Инк. filed Critical Промедиор, Инк.
Publication of RU2020111934A publication Critical patent/RU2020111934A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1716—Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
RU2020111934A 2013-10-08 2014-10-08 Способы лечения фиброзного рака RU2020111934A (ru)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361888269P 2013-10-08 2013-10-08
US61/888,269 2013-10-08
US201461992807P 2014-05-13 2014-05-13
US61/992,807 2014-05-13
US201462004836P 2014-05-29 2014-05-29
US201462004828P 2014-05-29 2014-05-29
US62/004,836 2014-05-29
US62/004,828 2014-05-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2016117775A Division RU2718056C2 (ru) 2013-10-08 2014-10-08 Способы лечения фиброзного рака

Publications (1)

Publication Number Publication Date
RU2020111934A true RU2020111934A (ru) 2020-04-29

Family

ID=52813618

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2020111934A RU2020111934A (ru) 2013-10-08 2014-10-08 Способы лечения фиброзного рака
RU2016117775A RU2718056C2 (ru) 2013-10-08 2014-10-08 Способы лечения фиброзного рака

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2016117775A RU2718056C2 (ru) 2013-10-08 2014-10-08 Способы лечения фиброзного рака

Country Status (10)

Country Link
US (2) US11020451B2 (cg-RX-API-DMAC7.html)
EP (2) EP3718558A1 (cg-RX-API-DMAC7.html)
JP (2) JP6636914B2 (cg-RX-API-DMAC7.html)
CN (2) CN114053395A (cg-RX-API-DMAC7.html)
AU (2) AU2014331954B2 (cg-RX-API-DMAC7.html)
CA (1) CA2926418A1 (cg-RX-API-DMAC7.html)
ES (1) ES2784234T3 (cg-RX-API-DMAC7.html)
PL (1) PL3054959T3 (cg-RX-API-DMAC7.html)
RU (2) RU2020111934A (cg-RX-API-DMAC7.html)
WO (1) WO2015054390A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2020111934A (ru) 2013-10-08 2020-04-29 Промедиор, Инк. Способы лечения фиброзного рака
WO2016168612A1 (en) * 2015-04-15 2016-10-20 Promedior, Inc. Methods for treating myeloproliferative disorders
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
JP7324210B2 (ja) * 2018-01-31 2023-08-09 ティダブリューアイ・バイオテクノロジー・インコーポレイテッド トファシチニブを含む局所製剤
CN112166111A (zh) * 2018-03-28 2021-01-01 布莱德治疗公司 治疗纤维化疾病的方法
CN108715865B (zh) * 2018-05-28 2021-09-21 福建师范大学 用于提高细胞转染效率的试剂组合物
CN119455003A (zh) 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
US20220202803A1 (en) * 2019-04-25 2022-06-30 Clear Creek Bio, Inc. Combination therapies including inhibitors of dihydroorotate dehydrogenase
CN112107556A (zh) * 2019-06-03 2020-12-22 北京大学 一种含砷纳米药物及其制备方法
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
AU2021213469B2 (en) * 2020-01-28 2026-06-04 Raziel Therapeutics Ltd. Compositions for the treatment of angiolipoma
KR102725907B1 (ko) * 2021-11-25 2024-11-04 성균관대학교산학협력단 파크리티닙을 이용한 항암제 내성 암 치료를 위한 병용 요법
EP4680215A1 (en) * 2023-03-17 2026-01-21 MDX Management LLC Compositions and methods for ameliorating adverse effects of therapies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
CA2135646A1 (en) 1992-05-11 1993-11-25 Kenneth G. Draper Method and reagent for inhibiting viral replication
JPH07509133A (ja) 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド 動物疾患の処置のための方法および剤
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
AU8525098A (en) 1997-07-24 1999-02-16 Inex Pharmaceuticals Corporation Liposomal compositions for the delivery of nucleic acid catalysts
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8012472B2 (en) * 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
US7763256B2 (en) 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
EP1863516A2 (en) * 2005-02-08 2007-12-12 Board of Regents, The University of Texas System Compositions and methods involving mda-7 for the treatment of cancer
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
EP2029173B1 (en) * 2006-06-26 2016-07-20 MacroGenics, Inc. Fc riib-specific antibodies and methods of use thereof
JP5220025B2 (ja) * 2006-12-04 2013-06-26 プロメディオール, インコーポレイテッド 線維症疾患を処置するための併用療法
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
WO2009009034A2 (en) * 2007-07-06 2009-01-15 Promedior, Inc Methods and compositions useful in the treatment of mucositis
US9884899B2 (en) * 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
PT2405929T (pt) * 2009-03-11 2018-07-23 Promedior Inc Métodos de tratamento para distúrbios autoimunes
PT2405928T (pt) 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
AU2010232591A1 (en) 2009-04-01 2011-11-03 Promedior, Inc. Pulmonary and nasal delivery of serum amyloid P
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
HUE041034T2 (hu) 2009-06-17 2019-05-28 Promedior Inc SAP-variánsok és alkalmazásuk
WO2013096847A1 (en) 2011-12-21 2013-06-27 Promedior, Inc. Serum amyloid p-antibody fusion proteins
JP2015069119A (ja) 2013-09-30 2015-04-13 パナソニック液晶ディスプレイ株式会社 表示装置
RU2020111934A (ru) 2013-10-08 2020-04-29 Промедиор, Инк. Способы лечения фиброзного рака
WO2016168612A1 (en) 2015-04-15 2016-10-20 Promedior, Inc. Methods for treating myeloproliferative disorders

Also Published As

Publication number Publication date
US11020451B2 (en) 2021-06-01
AU2014331954B2 (en) 2020-05-21
AU2020220139A1 (en) 2020-09-10
WO2015054390A1 (en) 2015-04-16
JP7140739B2 (ja) 2022-09-21
RU2718056C2 (ru) 2020-03-30
US20160235812A1 (en) 2016-08-18
EP3054959A4 (en) 2017-04-26
AU2014331954A1 (en) 2016-04-21
EP3054959A1 (en) 2016-08-17
US20210322515A1 (en) 2021-10-21
JP2020059752A (ja) 2020-04-16
EP3718558A1 (en) 2020-10-07
RU2016117775A3 (cg-RX-API-DMAC7.html) 2018-07-27
RU2016117775A (ru) 2017-11-15
JP2016539087A (ja) 2016-12-15
JP6636914B2 (ja) 2020-01-29
PL3054959T3 (pl) 2020-07-13
CA2926418A1 (en) 2015-04-16
EP3054959B1 (en) 2020-01-08
ES2784234T3 (es) 2020-09-23
CN105792831A (zh) 2016-07-20
CN114053395A (zh) 2022-02-18

Similar Documents

Publication Publication Date Title
RU2016117775A (ru) Способы лечения фиброзного рака
JP2016539087A5 (cg-RX-API-DMAC7.html)
EP3197493B1 (en) Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
JP2018512164A5 (cg-RX-API-DMAC7.html)
US20220313642A1 (en) Tyrosine derivatives and compositions comprising them
JP5623016B2 (ja) 癌治療法およびそれに用いる医薬組成物
CN1753665A (zh) 作为红细胞生成刺激剂的中链长脂肪酸类、甘油酯类和类似物
RU2017139122A (ru) Способы лечения миелопролиферативных нарушений
CA2952424A1 (en) Treating myelomas
US11214805B2 (en) Targeted nanocarriers for the administration of immunosuppressive agents
US20210128725A1 (en) Cytotoxic lipid particles targeted to tumor-associated myeloid cells (tamcs) and synergized with radiation therapy for treating glioblastoma
JP2022153587A (ja) チロシン誘導体及びそれらを含む組成物
CN100409895C (zh) 用于治疗白血病和淋巴瘤的阿普立定组合
US11466054B2 (en) Inhibitors of metastasis
JP2022534724A5 (cg-RX-API-DMAC7.html)
KR20260018053A (ko) Bcl2 억제제에 노출 이력이 없는 대상체의 암 치료 방법
KR20260018046A (ko) 이전의 면역 관문 억제제 노출 이력이 있는 대상체의 암 치료 방법
WO2023122577A2 (en) Methods of treating cancer using liposomal particles comprising anticancer agents and pharmaceutical compositions related thereto
US20210386736A1 (en) Combination therapy for treating cancer
WO2007047334A1 (en) Prevention and treatment of drug-associated ocular side effects with a cyclosporin
HK40056547A (en) Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
WO2025132723A1 (en) Dhp-i inhibitors for use as neuroprotectants and in the treatment of neuroinflammatory damages of the visual pathway
WO2025090844A1 (en) Methods of treating cancer associated with reduced interleukin 1 beta expression
US12447165B2 (en) Intratumoral vein-formation promoting agent
TH2001007208A (th) องค์ประกอบสองฟังก์ชั่นในการบำบัดรักษาโรคมะเร็ง